Subjects: ARTRITE REUMATOIDE (TERAPIA), VACINAS, POLISSACARÍDEOS BACTERIANOS, NECROSE
ABNT
AIKAWA, Nadia E. et al. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine, v. 33, p. 604-609, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2014.12.030. Acesso em: 13 jun. 2024.APA
Aikawa, N. E., França, I. L. A., Ribeiro, A. C., Sallum, A. M. E., Bonfá, E., & Silva, C. A. (2015). Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine, 33, 604-609. doi:10.1016/j.vaccine.2014.12.030NLM
Aikawa NE, França ILA, Ribeiro AC, Sallum AME, Bonfá E, Silva CA. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy [Internet]. Vaccine. 2015 ; 33 604-609.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1016/j.vaccine.2014.12.030Vancouver
Aikawa NE, França ILA, Ribeiro AC, Sallum AME, Bonfá E, Silva CA. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy [Internet]. Vaccine. 2015 ; 33 604-609.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1016/j.vaccine.2014.12.030